Does parathyroid hormone affect erythropoietin therapy in dialysis patients?

Medical Principles and Practice

Volumn 16, Issue 1, 2006, Pages 63-67

  Al Hilali, Nabieh ^a   Al Humoud, Hani ^a,b   Ninan, Vadakethu T ^a   Nampoory, Mangalathillam R N ^a   Puliyclil, Mini A ^b   Johny, Kaivilayil V ^a,b  

^a MUBARAK AL KABEER HOSPITAL   (Kuwait)

^b KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Anemia; Hemodialysis; Hyperparathyroidism; Peritoneal dialysis; Recombinant human erythropoietin

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; ANTIHYPERTENSIVE AGENT; CALCIUM; CREATININE; HEMOGLOBIN; NITROGEN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; RECOMBINANT ERYTHROPOIETIN; UREA; VITAMIN;

ADOLESCENT; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE BLOOD LEVEL; DRUG RESPONSE; ERYTHROPOIETIN RESISTANCE INDEX; FEMALE; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERPARATHYROIDISM; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ERYTHROPOIETIN; FEMALE; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; PARATHYROID HORMONE; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS;

EID: 33845543455     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096143     Document Type: Article

References (22)

1. Eschbach J, Adamson J: Recombinant human erythropoietin: implication for nephrology. Am J Kidney Dis 1988;11:203-209.
2. Macdougall IC: Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Open Nephrol Hypertens 1994;3:620-625.
3. Rosenlof K, Fyhrquist F, Tenhunen R: Erythropoietin, aluminum, and anemia in patients on haemodialysis. Lancet 1990;335:247-249.
4. Nakamoto H, Kanno Y, Okada H, Suzuki H: Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis. Adv Perit Dial 2004;20:111-116.
5. Muirhead N, Hodsman AB: Occult infection and resistance of anemia to rHUEPO therapy in renal failure. Nephrol Dial Transplant 1990;5:232-234.
6. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in anemia. N Engl J Med 1993;328:171-175.
7. Drueke TB: Modulating factors in hematopoietic response to erythropoietin. Am J Kidney Dis 1991;18:87-92.
8. National Kidney Foundation, Kidney-Dialysis Outcomes Quality Initiative: K/DOQI Clinical practice guidelines: anemia of chronic kidney disease. Am J Kidney Dis 2001;37(suppl 1):S182-S238.
9. National Kidney Foundation, Kidney-Dialysis Outcomes Quality Initiative: K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;37(suppl 3):S182-S238.
10. Shih-Ping Hsu, Yu-Sen Peng, Mei-Fen Pai, Kuan-Yu Hung, Tun-jun Tsai: Infuence of relative hypoparathyroidism on the responsiveness to recombinant human erythropoietin in hemodialysis patients. Blood Purif 2003;21:220-224.
11. Komatsuda A, Hirokawa M, Haseyama T, et al: Human parathyroid hormone does not influence human erythropoiesis in vitro. Nephrol Dial Transplant 1998;13:2088-2091.
12. Gunnell J, Yeun JY, Depner TA, Kaysen GA: Acute phase response predicts erythropoietin resistance in haemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999;33:63-72.
13. Coronel F, Herrero JA, Montenegro J, Fernandez C, Gandara A, Conesa J, Rivera MT, Torrente J, Portoles J, Gomez-Martino JR: Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis. J Nephrol 2003;16:697-702.
14. Zappacosta AR, Caro J, Erslev AJ: Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. Am J Med 1982;72:53-57.
15. DePaepe MBJ, Schelstraete KHG, Ringoir SMG, Lameire NH: Influence of continuous ambulatory peritoneal dialysis on the anemia of end-stage renal disease. Kidney Int 1983;23:744-748.
16. Guolo M, Machalinski C, Biscoglio M, Stella AM, Franco C, Pataro L, de Salamanca RE, Batlle A: Inhibition of erythrocyte aminolevulinate dehydratase by a 56.2-kD peptide from uremic plasma. Exp Nephrol 1999;7:236-241.
17. Fontanellas A, Coronel F, Santos JL, Herrero JA, Moran MJ, Guerra P, Tornero F, de Salamanca RE: Heme biosynthesis in uremic patients on CAPD or hemodialysis. Kidney Int 1994;45:220-223.
18. Niwa T, Yazawa T, Kodoma T, Uehara Y, Maeda K, Yamada K: Efficient removal of albumin-bound furancarboxylic acid; an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 1990;56:241-245.
19. Kcomt J, Sotelo C, Raja R: Influence of adynamic bone disease on responsiveness to recombinant erythropoietin in peritoneal dialysis patients. Adv Perit Dial 2000;16:294-296.
20. Kimata N, Akiba T, Pisoni RL, Albert JM, Satayathum S, Cruz JM, Akizawa T, Andreucci VE, Young EW, Port FK: Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2005;20:927-935.
21. Meytes D, Bogin E, Ma A, Dukes P, Massry SG: Effects of parathyroid hormone on erythropoiesis. J Clin Invest 1981;67:1263-1269.
22. Urena P, Eckardt, KU, Sarfati, E, Zingraff J, Zins B, Roullet JB, Roland E, Drueke T, Kurtz A: Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: effect of parathyroidectomy. Nephron 1991;59:384-393.